ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO998

Genome Wide Non HLA Alloimmunity Contributes to Graft Loss after Kidney Transplantation

Session Information

Category: Transplantation

  • 1702 Transplantation: Clinical and Translational


  • Oberbauer, Rainer, Medical University of Vienna, Vienna, Austria
  • Reindl-Schwaighofer, Roman, Medical University of Vienna, Vienna, Austria
  • Kainz, Alexander, Department of Nephrology, Vienna, Austria
  • Heinzel, Andreas, Medical University of Vienna, Vienna, Vienna, Austria
  • Jelencsics, Kira, Medical University Vienna, Vienna, Austria
  • Hruba, Petra, Institute for Clinical and Experimental Medicine, Prague, Czechia
  • Viklicky, Ondrej, Institute for Clinical and Experimental Medicine, Department of Nephrology, Prague, Czechia
  • Bohmig, Georg, Medical University Vienna, Vienna, Austria
  • Fischer, Gottfried, Medical University of Vienna, Vienna, Austria
  • Keating, Brendan, University of Pennsylvania, Philadelphia, Pennsylvania, United States

HLA alloimmunity is the main cause of renal transplant loss but the contribution of nonHLA donor recipient mismatches on a genome wide basis has not been elucidated thoroughly yet.


We made use of the iGeneTrain consortium and genotyped 753 donors and 863 corresponding recipients using the Affymetrix Axiom Tx GWAS Array (Affymetrix). Raw genotypes were after an initial quality control phased and imputed with impute2 using GoNL and 1KG data as reference panels. The ensemble Variant Effect Predictor and ANNOVAR were used for SNP annotation.
The number of recipients with a median follow up of 6.5 years were obtained from the Vienna and Prague transplant cohort study. The main available outcomes are death censored graft loss and eGFR slope after transplantation. HLA incompatibility and other clinical variables known to influence these outcomes are available.
In a first preliminary analysis elucidating the effect of donor recipient non-synonymous SNP (nsSNP) mismatches (MM) on graft survival a Cox model was employed to analyze the association of nsSNP MM with graft survival. For this preliminary analysis 180 donor recipient pairs with 36 events were available.


The association of nsSNP MM with graft survival showed a trend towards elevated risk for death censored graft loss (table).

Table: Multivariable Cox model relating the time of graft survival to donor recipient HLA MM and nsSNP MM.
A follow up study utilizing the full cohort and imputation results will be performed in the next months prior to the meeting. Further custom peptide arrays (NimbleGen/Roche) holding 172,943 features will be employed to uncover the formation of antibodies in case of donor recipient LoF and nsSNP MM.


NonHLA alloimmunity independently contributes to graft loss after kidney transplantation.

Cox model
ParameterHR95CI lower95CI higherp-value
HLA MM1.291.051.600.017
SNP a 1001.580.783.210.201